NEW YORK (GenomeWeb News) – Transrenal molecular diagnostics company Trovagene said today that its revenues in the second quarter dropped 49 percent year over year.

The San Diego-based firm recorded revenues of $41,000 for the quarter ended June 30, down from $80,000 a year ago. Revenues for the recently completed quarter and Q2 2011 were in the form only of royalty income, and the year-over-year reduction resulted from the termination of an agreement with Sequenom in 2011, Trovagene said in its Form 10-Q filed with the US Securities and Exchange Commission.